A randomized double blind parallel controlled study on the effect of decoction of honeysuckle and rattan on the level of hsCRP in patients with carotid atherosclerosis

Not Applicable

• Conditions: Carotid atherosclerosis

• Registration Number: ITMCTR2000003331
• Lead Sponsor: Dongzhimen Hospital of Beijing University of Traditional Chinese Medicine

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 20 February 2023

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

1. The patients with carotid atherosclerotic plaques were diagnosed by color Doppler ultrasound;
2. hsCRP >= 2 mg/L;
3. The syndrome differentiation of traditional Chinese medicine is mainly the patients with stasis heat and internal depression;
4. Patients between 40 and 70 years old, regardless of gender;
5. Patients who can take medicine for a long time;
6. Patients who have informed consent and signed the informed consent.

Exclusion Criteria

1. Patients with acute stage of cardiovascular and cerebrovascular diseases;
2. Patients with previous history of cerebral hemorrhage;
3. Patients with other active ulcers and bleeding tendency who take anticoagulants (such as warfarin) for a long time;
4. Patients with serious arrhythmia, atrial fibrillation and heart failure;
5. Patients with severe liver, kidney, hematopoietic system, endocrine system, respiratory system, hypertension, infectious and non infectious inflammation, immune related and other primary diseases, whose liver function is more than 1.5 times higher than the upper limit of the normal value, and whose Cr is higher than the normal value;
6. Patients who are using antidotal and blood activating drugs, antibiotics, hormones, immunosuppressants, IL-1 ß monoclonal antibodies and other drugs that affect hsCRP;
7. Patients with gastrointestinal dysfunction, diarrhea and abdominal distention;
8. Pregnant or lactating women, women with a recent pregnancy plan;
9. Patients with allergic constitution;
10. Any other life-threatening or serious disease that cannot be treated for 3 months and thus affects the evaluation results;
11. Other diseases or psychosis that may limit efficacy evaluation or patient follow-up in the opinion of researchers;
12. Patients who have participated in clinical trials of other drugs in the past 4 weeks.

Study & Design

• Study Type: Interventional study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
High sensitive C-reactive protein;

Secondary Outcome Measures

Name	Time	Method
Fasting blood glucose;Four items of blood lipid;Interleukin-6;